Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6.58 USD | -0.75% | -4.15% | -6.00% |
May. 17 | HC Wainwright Adjusts Kala Pharmaceuticals Price Target to $18 From $21, Maintains Buy Rating | MT |
Apr. 02 | HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.00% | 18.67M | |
+37.58% | 705B | |
+32.59% | 583B | |
-3.22% | 364B | |
+19.98% | 332B | |
+5.31% | 291B | |
+16.91% | 238B | |
-3.56% | 210B | |
+10.40% | 209B | |
+9.20% | 169B |
- Stock Market
- Equities
- KALA Stock
- News KALA BIO, Inc.
- Oppenheimer Adjusts Kala Pharmaceuticals Price Target to $5 From $8, Maintains Outperform Rating